

International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,¹ notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, e.g., for List 60 Prop. INN not later than 31 May 1989.

The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

Action and Use

The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded proposed INNs. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature these descriptors will not be included in the Cumulative Lists of INNs.

Proposed International Nonproprietary Names (Prop. INN): List 60²

Comprehensive information on the INN programme can be found in WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances* Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 (price: Sw fr 6.-); an account of this publication will be found in Annex 2 of the present List. All names from Lists 1-47 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in: *International Nonproprietary Names (INN) for Pharmaceutical Substances, Cumulative List No. 6*, 1982, World Health Organization, Geneva (ISBN 92 4 056013 0) (price: Sw fr. 55.-). This publication consists, in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN)—in Latin, English, French, Russian, and Spanish—published up to April 1982. The printout also indicates in which of the 47 individual lists of proposed names and 21 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulae and Chemical Abstracts Service registry numbers. For easy reference, national nonproprietary names that differ from INN, molecular formulae, and Chemical Abstracts Service registry numbers are indexed in a series of annexes. A final annex describes the procedure for selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French.

These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of *WHO Drug Information*. Orders from countries where sales agents have not yet been appointed may be addressed to: World Health Organization, Distribution and Sales Service, 1211 Geneva 27, Switzerland.

¹ Text adopted by the Executive Board of WHO in resolution EB15 R7 (*Off. Rec. Wld Hlth Org.*, 1955, **60**, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wld Hlth Org.*, 1969, **173**, 10).


² Other lists of proposed and recommended international nonproprietary names can be found in *Cumulative List No. 7*, 1988.

Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


abecarnilum
abecarnil

isopropyl 6-(benzyloxy)-4-(methoxymethyl)-9H-pyrido[3,4-b]indole-3-carboxylate
 $C_{24}H_{24}N_2O_4$ 111841-85-1 *partial benzodiazepine receptor agonist*




acemannanum
acemannan

(1→4)-β-D-mannurono-2-acetamido-2-deoxy-β-D-gluco-β-D-mannan 3-acetate
— 110042-95-0 *antiviral, immunomodulator*




acidum tiludronicum
tiludronic acid

[[p-chlorophenyl]thio]methylene]diphosphonic acid
 $C_7H_8ClO_6P_2S$ 89987-06-4 *antiarthritic*



actisomidum
actisomide

(±)-cis-4-[2-(diisopropylamino)ethyl]-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-3H-pyrido[1,2-c]pyrimidin-3-one
 $C_{23}H_{33}N_3O$ 96914-39-5 *antidysrhythmic*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use

ambamustinum
ambamustine

N-[3-[*m*-[bis(2-chloroethyl)amino]phenyl]-*N*-[3-(*p*-fluorophenyl)-*L*-alanyl]-*L*-alanyl]-*L*-methionine, ethyl ester
 $C_{29}H_{39}Cl_2FN_4O_4S$ 85754-59-2 *antineoplastic*




antithrombinum III
antithrombin III (protein)

antithrombin III. The source of the product should be indicated
— —


apafantum
apafant

4-[3-[4-(*o*-chlorophenyl)-9-methyl-6*H*-thieno[3,2-*f*]-*s*-triazolo[4,3-*a*]-[1,4]diazepin-2-yl]propionyl]morpholine
 $C_{22}H_{22}ClN_5O_2S$ 105219-56-5 *platelet-activating factor antagonist*



argimesna
argimesna

L-arginine mono(2-mercaptoethanesulfonate)
 $C_8H_{20}N_4O_5S_2$ 106854-46-0 *antidote*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


atosibanum
atosiban

1-(3-mercaptopropionic acid)-2-[3-(*p*-ethoxyphenyl)-*D*-alanine]-4-L-threonine-
8-L-ornithineoxytocin
 $C_{43}H_{67}N_{11}O_{12}S_2$ 90779-69-4 *oxytocin antagonist*




azetirelinum
azetirelin

(-)-*N*-[[[(2*S*)-4-oxo-2-azetidiny]carbonyl]-L-histidyl-L-prolinamide
 $C_{15}H_{20}N_6O_4$ 95729-65-0 *thyrotropin releasing hormone analogue*




baxitozinum
baxitozine

(*E*)-3-(3,4,5-trimethoxybenzoyl)acrylic acid
 $C_{13}H_{14}O_6$ 84386-11-8 *antiulcer*



bepafantum
bepafant

4-[[[6-(*o*-chlorophenyl)-8,9-dihydro-1-methyl-4*H*,7*H*-cyclopenta[4,5]thieno-
[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepin-8-yl]carbonyl]morpholine
 $C_{23}H_{22}ClN_5O_2S$ 114776-28-2 *platelet-activating factor antagonist*




*Proposed International
Nonproprietary Name (Latin, English)*

*Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use*


binfloxacinum
binfloxacin

7-{1,4-diazabicyclo[3.2.2]non-4-yl}-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
C₁₉H₂₂FN₃O₃ 108437-28-1 *antibacterial (vet)*




binizolastum
jizolast

1-(piperidinomethyl)-4-propyl-*s*-triazolo[4,3-*a*]quinazolin-5(4*H*)-one
C₁₈H₂₃N₅O 86662-54-6 *antiasthmatic*




bisaramilum
bisaramil

syn-3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]non-9-yl *p*-chlorobenzoate
C₁₇H₂₃ClN₂O₂ 89194-77-4 *antidysrhythmic*



bretazenilum
bretazenil

tert-butyl (5*S*)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9*H*-imidazo-[1,5-*a*]pyrrolo[2,1-*c*][1,4]benzodiazepine-1-carboxylate
C₁₉H₂₀BrN₃O₃ 84379-13-5 *partial benzodiazepine receptor agonist*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


bunaprolastum
bunaprolast

2-butyl-4-methoxy-1-naphthol acetate
 $C_{17}H_{20}O_3$ 99107-52-5 *antiasthmatic*




cefprozilum
cefprozil

(6*R*,7*R*)-7-[(*R*)-2-amino-2-(*p*-hydroxyphenyl)acetamido]-8-oxo-3-[(*Z*)-propenyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
 $C_{18}H_{19}N_3O_5S$ 92665-29-7 *antibiotic*




ceftibutenum
ceftibuten

(+)-(6*R*,7*R*)-7-[(*Z*)-2-(2-amino-4-thiazolyl)-4-carboxycrotonamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
 $C_{15}H_{14}N_4O_6S_2$ 97519-39-6 *antibiotic*



cilofunginum
cilofungin

1-[(4*R*,5*R*)-4,5-dihydroxy-*N*²-[*p*-(octyloxy)benzoyl]-L-ornithine]echinocandin B or (4*R*,5*R*)-4,5-dihydroxy-*N*²-[*p*-(octyloxy)benzoyl]-L-ornithyl-L-threonyl-*trans*-4-hydroxy-L-prolyl-(*S*)-4-hydroxy-4-(*p*-hydroxyphenyl)-L-threonyl-L-threonyl-(3*S*,4*S*)-3-hydroxy-4-methyl-L-proline cyclic (6→1)-peptide
 $C_{49}H_{71}N_7O_{17}$ 79404-91-4 *antifungal*



Proposed International
Nonproprietary Name (Latin, English)


Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use

colextranum
colextran

dextran 2-(diethylamino)ethyl ether
9015-73-0
antihypercholesterolaemic, antihyperlipidaemic

cyromazinum
cyromazine


cyclopropylmelamine
 $C_6H_{10}N_6$ 66215-27-8
antiparasitic (vet.)



iz)


delfaprazinum
delfaprazine

1-(α^2 -phenyl-2,5-xylyl)piperazine
 $C_{18}H_{22}N_2$ 117827-81-3
antidepressant




dizocilpinum
dizocilpine

(+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine
 $C_{18}H_{15}N$ 77086-21-6
antiepileptic



doretinelum
doretinel

(\pm)-p-[(E)-2-(5,6,7,8-tetrahydro-7-hydroxy-5,5,8,8-tetramethyl-2-naphthyl)-propenyl]benzyl alcohol
 $C_{24}H_{30}O_2$ 104561-36-6
keratolytic




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


elbanizinium
elbanizine

1-[2-[(2,6-dimethyl-3-nitro-4-pyridyl)amino]ethyl]-4-(diphenylmethyl)-
piperazine
 $C_{26}H_{31}N_5O_2$ 110629-41-9 *histamine H_1 -antagonist*




endixaprinum
endixaprine

1-[6-(2,4-dichlorophenyl)-3-pyridazinyl]-4-piperidinol
 $C_{15}H_{15}Cl_2N_3O$ 93181-85-2 *antiepileptic, hypnotic*




erbulozolum
erbulozole

ethyl (±)-*cis*-*p*-[[[2-(imidazol-1-ylmethyl)-2-(*p*-methoxyphenyl)-1,3-dioxolan-4-yl]methyl]thio]carbanilate
 $C_{24}H_{27}N_3O_5S$ — *radiosensitizing agent*



esafloxacinum
esafloxacin

(±)-7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-
1,8-naphthyridine-3-carboxylic acid
 $C_{15}H_{17}FN_4O_3$ 79286-77-4 *antibacterial*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


gadopenamidum
gadopenamide

[N,N'-bis[2-[(carboxymethyl)[(morpholinocarbonyl)methyl]amino]ethyl]-
glycinato(3-)]gadolinium
 $C_{22}H_{34}GdN_5O_{10}$ 117827-80-2 paramagnetic contrast medium




ibafloxacinum
ibafloxacin

9-fluoro-6,7-dihydro-5,8-dimethyl-1-oxo-1H,5H-benzo[*ij*]quinolizine-
2-carboxylic acid
 $C_{15}H_{14}FNO_3$ 91618-36-9 antibacterial




imidaprilum
imidapril

(4S)-3-[(2S)-N-[(1S)-1-carboxy-3-phenylpropyl]alanyl]-1-methyl-2-oxo-
4-imidazolidinecarboxylic acid, 3-ethyl ester
 $C_{26}H_{27}N_3O_6$ 89371-37-9 angiotensin-converting enzyme inhibitor



iotrisidum
iotriside

(±)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methyl-1,3,5-benzenetri-
carboxamide
 $C_{16}H_{20}I_3N_3O_7$ 79211-34-0 contrast medium




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


irtemazolum
irtemazole

(±)-5-(*α*-imidazol-1-ylbenzyl)-2-methylbenzimidazole
C₁₈H₁₆N₄ 115574-30-6 *uricosuric*




ivarimodum
ivarimod

4-[[[(3*aR*,3*bS*,5*aR*,6*R*,9*aR*,9*bR*,11*R*,11*aR*)-1,2,3,3*a*,4,5,5*a*,6,7,8,9,9*a*,9*b*,10,11,11*a*-hexadecahydro-2-(2-hydroxyethyl)-12-isopropyl-6,9*a*-dimethyl-1,3-dioxo-3*b*,11-etheno-3*bH*-naphth[2,1-*e*]isoindol-6-yl]carbonyl]morpholine
C₃₀H₄₄N₂O₅ 53003-81-9 *immunomodulator*




lansoprazolum
lansoprazole

2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
C₁₈H₁₄F₃N₃O₂S 103577-45-3 *antiulcer*



laprafyllinum
laprafylline

8-[2-[4-(diphenylmethyl)-1-piperazinyl]ethyl]-
3-isobutyl-1-methylxanthine
C₂₉H₃₆N₆O₂ 90749-32-9 *antiasthmatic*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


lodelabenum
lodelaben

(±)-2-chloro-4-(1-hydroxyoctadecyl)benzoic acid
 $C_{25}H_{41}ClO_3$ 93105-81-8 *antiarthritic*




loracarbefum
loracarbef

(6*R*,7*S*)-7-[(*R*)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-1-azabi-
cyclo[4.2.0]oct-2-ene-2-carboxylic acid
 $C_{18}H_{16}ClN_3O_4$ 76470-66-1 *antibiotic*




loreclezolum
loreclezole

(*Z*)-1-(β,2,4-trichlorostyryl)-1*H*-1,2,4-triazole
 $C_{10}H_6Cl_3N_3$ 117857-45-1 *antiepileptic*




lorpiprazolum
lorpiprazole

(±)-*cis*-5,5a,6,7,8,8a-hexahydro-3-[2-[4-(*α,α,α*-trifluoro-*m*-tolyl)-
1-piperazinyl]ethyl]cyclopenta[3,4]pyrrolo[2,1-*c*]-*s*-triazole
 $C_{21}H_{26}F_3N_5$ 108785-69-9 *anxiolytic*



mequitazii iodidum
mequitazium iodide

(±)-1-methyl-3-(phenothiazin-10-ylmethyl)quinuclidinium iodide
 $C_{21}H_{25}IN_2S$ 101396-42-3 *antiasthmatic*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


meropenemum
meropenem

(4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-(dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
C₁₇H₂₅N₃O₅S 96036-03-2 antibiotic




mertiatidum
mertiatide

N-[*N*-(mercaptoacetyl)glycyl]glycyl]glycine
C₈H₁₃N₃O₅S 66516-09-4 diagnostic aid




metalkonii chloridum
metalkonium chloride

benzyl[(dodecylcarbamoyl)methyl]dimethylammonium chloride
C₂₃H₄₁ClN₂O 100-95-8 disinfectant




methoprenum
methoprene

isopropyl (2*E*,4*E*)-(7*S*)-11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate
C₁₉H₃₄O₃ 40596-69-8 lenticide, ovicide



mitoflaxonom
mitoflaxone

4-oxo-2-phenyl-4*H*-1-benzopyran-8-acetic acid
C₁₇H₁₂O₄ 87626-55-9 cytostatic




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


moexiprilum
moexipril

(3S)-2-[(2S)-N-[(1S)-1-carboxy-3-phenylpropyl]alanyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester
C₂₇H₃₄N₂O₇ 103775-10-6 *angiotensin-converting enzyme inhibitor*




loxiraprinum
moxiraprine

p-[5-methyl-6-[(2-morpholinoethyl)amino]-3-pyridazinyl]phenol
C₁₇H₂₂N₄O₂ 82239-52-9 *antiparkinson, antidepressant*




nanterinonum
nanterinone

6-(2,4-dimethylimidazol-1-yl)-8-methylcarbostyryl
C₁₅H₁₅N₃O 102791-47-9 *positive inotropic agent*




napirimusum
napirimus

1-methyl-4-(1-naphthoyl)pyrrole-2-carboxylic acid
C₁₇H₁₃NO₃ 70696-66-1 *immunosuppressive agent*



natrii pentosani polysulfas
pentosan polysulfate sodium

(1→4)-β-D-xylan 2,3-bis(hydrogen sulfate), sodium salt
(C₅H₆Na₂O₁₀S₂)_n — *anticoagulant*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


naxagolidum
naxagolide

(+)-(4*aR*,10*bR*)-3,4,4*a*,5,6,10*b*-hexahydro-4-propyl-2*H*-naphth[1,2-*b*]-
1,4-oxazin-9-ol
 $C_{15}H_{21}NO_2$ 88058-88-2 dopamine receptor agonist




neldazosinum
neldazosin

(±)-1-(4-amino-6,7-dimethoxy-2-quinazoliny)-4-(3-hydroxybutyryl)piperazine
 $C_{18}H_{25}N_5O_4$ 109713-79-3 α_1 -adrenoreceptor antagonist




nemadectinum
nemadectin

(6*R*,23*S*,25*S*)-5-*O*-demethyl-28-deoxy-25-[(*E*)-1,3-dimethyl-1-butenyl]-
6,28-epoxy-23-hydroxymilbemycin B
 $C_{36}H_{52}O_8$ 102130-84-7 antiparasitic (vet.)



nicaravenum
nicaraven

(±)-*N,N'*-propylenebis[nicotinamide]
 $C_{15}H_{16}N_4O_2$ 79455-30-4 cerebral vasodilator




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


orlipastatum
orlipastat

N-formyl-L-leucine, ester with (3*S*,4*S*)-3-hexyl-4-[(2*S*)-2-hydroxytridecyl]-
2-oxetanone
 $C_{29}H_{53}NO_5$ 96829-58-2 *pancreatic lipase inhibitor*




oxamisolum
oxamisole

(±)-2,3,6,7-tetrahydro-2-phenylimidazo[1,2-*a*]pyridin-8(5*H*)-one, dimethyl
acetal
 $C_{16}H_{20}N_2O_2$ 99258-56-7 *immunomodulator*




pelretinum
pelretin

(*E,E,E*)-*p*-[4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3,5-hexa-
trienyl]benzoic acid
 $C_{23}H_{28}O_2$ 91587-01-8 *keratolytic*




pentamorphonum
pentamorphone

7,8-didehydro-4,5*a*-epoxy-3-hydroxy-17-methyl-14-(pentylamino)morphinan-
6-one
 $C_{22}H_{28}N_2O_3$ 68616-83-1 *narcotic analgesic*



pentigetidum
pentigetide

N^2 -[1-[*N*-(*N*-*L*-aspartyl-L-seryl)-L-*a*-aspartyl]-L-prolyl]-L-arginine
 $C_{22}H_{38}N_8O_{11}$ 62087-72-3 *immunomodulator*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


performedilum
performedil

(±)-2',4',6'-trimethoxy-4-(3-methylpiperidino)butyrophenone
C₁₉H₂₉NO₄ 92268-40-1
peripheral vasodilator




pioglitazonum
pioglitazone

(±)-5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
C₁₉H₂₀N₂O₃S 111025-46-8
antidiabetic




posatirelinum
posatirelin

(2S)-N-[(1S)-1-[[[(2S)-2-carbamoyl-1-pyrrolidinyl]carbonyl]-3-methylbutyl]-6-oxopipercolamide
C₁₇H₂₈N₄O₄ 78864-73-0
thyrotropin releasing hormone analogue




pravadolinum
pravadoline

p-methoxyphenyl 2-methyl-1-(2-morpholinoethyl)indol-3-yl ketone
C₂₃H₂₆N₂O₃ 92623-83-1
analgesic



quinaprilatum
quinaprilat

(3S)-2-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid
C₂₃H₂₆N₂O₅ 85441-60-7
angiotensin-converting enzyme inhibitor




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


quineloranum
quinelorane

(-)-(5*aR*,9*aR*)-2-amino-5,5*a*,6,7,8,9,9*a*,10-octahydro-
6-propylpyrido[2,3-*g*]quinazoline
 $C_{14}H_{22}N_4$ 97466-90-5 *D*₂-dopamine receptor agonist



renzapridum
renzapride


(±)-*endo*-4-amino-*N*-1-azabicyclo[3.3.1]non-4-yl-5-chloro-*o*-anisamide
 $C_{16}H_{22}ClN_2O_2$ 112727-80-7 *antiemetic*



riluzol


riluzolum
riluzole

2-amino-6-(trifluoromethoxy)benzothiazole
 $C_8H_5F_3N_2OS$ 1744-22-5 *antiepileptic*




romazaritum
romazarit

2-[[2-(*p*-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methylpropionic acid
 $C_{15}H_{19}ClNO_4$ 109543-76-2 *nonsteroidal anti-inflammatory*



semduramicinum
semduramicin

(3*R*,4*S*,5*S*,6*R*,7*S*,22*S*)-23,27-didemethoxy-2,6,22-tridemethyl-5,11-di-
O-demethyl-6-methoxy-22-[[[(2*S*,5*S*,6*R*)-tetrahydro-5-methoxy-6-methyl-
2*H*-pyran-2-yl]oxy]ionomycin A or
(2*R*,3*S*,4*S*,5*R*,6*S*)-tetrahydro-2,4-dihydroxy-6-[(1*R*)-1-[(2*S*,5*R*,7*S*,8*R*,9*S*)-
9-hydroxy-2,8-dimethyl-2-[(2*R*,5*S*)-tetrahydro-5-methyl-5-[(2*R*,3*S*,5*R*)-tetra-
hydro-5-[(2*S*,3*S*,5*R*,6*S*)-tetrahydro-6-hydroxy-3,5,6-trimethyl-2*H*-pyran-2-yl]-
3-[[[(2*S*,5*S*,6*R*)-tetrahydro-5-methoxy-6-methyl-2*H*-pyran-2-yl]oxy]-2-furyl]-
2-furyl]-1,6-dioxaspiro[4.5]dec-7-yl]ethyl]-5-methoxy-3-methyl-2*H*-pyran-
2-acetic acid
 $C_{45}H_{74}O_{16}$ 113378-31-7 *coccidiostatic*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


sergolexolum
serglexole

trans-4-methoxycyclohexyl 1-isopropyl-6-methylergoline-8 β -carboxylate
C₂₆H₃₆N₂O₃ 108674-86-8 *antimigraine*




siguazodanum
siguazodan

2-cyano-1-methyl-3-[*p*-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]guanidine
C₁₄H₁₆N₆O 99591-83-0 *positive inotropic agent*




spiraprilatum
spiraprilat

(8*S*)-7-[(*S*)-*N*[(*S*)-1-carboxy-3-phenylpropyl]alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
C₂₀H₂₈N₂O₅S₂ 83602-05-5 *angiotensin-converting enzyme inhibitor*



tabilautidum
tabilautide

threo-6-carbamoyl-*N*²-[*N*-(*N*-lauroyl-L-alanyl)-D- γ -glutamyl]-L-lysine
C₂₇H₄₈N₅O₈ 78088-46-7 *immunomodulator*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


tandospironum
tandospirone

(1*R**,2*S**,3*R**,4*S**)-*N*-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-
2,3-norbornanedicarboximide
C₂₁H₂₈N₃O₂ 87760-53-0 *anxiolytic*




tazobactamum
tazobactam

(2*S*,3*S*,5*R*)-3-methyl-7-oxo-3-(1*H*-1,2,3-triazol-1-ylmethyl)-4-thia-
1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 4,4-dioxide
C₁₀H₁₂N₄O₅S 89786-04-9 *antibiotic*



temurtidum
temurtide

2-acetamido-3-*O*-[[(1*R*)-1-[(1*S*,2*R*)-1-[(1*R*)-1-carbamoyl-3-carboxypropyl]-
carbamoyl]-2-hydroxypropyl]carbamoyl]ethyl]-2-deoxy-
D-glucopyranose
C₂₀H₃₄N₄O₁₂ 66112-59-2 *immunomodulator*




thrombinum
thrombin

thrombin or E.C. 3.4.21.5. The source of the product should be indicated.



thymocartinum
thymocartin

N-[*N*-(*N*²-L-arginyl-L-lysyl)-L-α-aspartyl]-L-valine
C₂₁H₄₀N₈O₇ 85466-18-8 *immunomodulator*




Proposed International
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae
Chemical Abstracts Service (CAS) registry number
Action and use


tosufloxacinum
tosufloxacin

(±)-7-(3-amino-1-pyrrolidiny)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
C₁₉H₁₅F₃N₄O₃ 108138-46-1 antibacterial




trandolaprilatum
trandolaprilat

(2S,3aR,7aS)-1-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid
C₂₂H₃₀N₂O₅ 87679-71-8 angiotensin-converting enzyme inhibitor




umespironum
umespiron

N-butyl-N'-[4-[4-(α-methoxyphenyl)-1-piperazinyl]butyl]-2,2-dimethyl-1,1,3,3-propanetetracarboxylic 1,3 : 1,3-diimide
C₂₈H₄₀N₄O₅ 107736-98-1 anxiolytic




venlafaxinum
venlafaxine

(±)-1-[α-[(dimethylamino)methyl]-p-methoxybenzyl]cyclohexanol
C₁₇H₂₇NO₂ 93413-69-5 antidepressant



zilpaterolum
zilpaterol

(±)-trans-4,5,6,7-tetrahydro-7-hydroxy-6-(isopropylamino)imidazo-[4,5,1-jk][1]benzazepin-2(1H)-one
C₁₄H₁₆N₃O₂ 117827-79-9 β₂-adrenoreceptor agonist



AMENDMENTS TO PREVIOUS LISTS

WHO Chronicle, Vol. 25, No. 9, 1971

Proposed International Nonproprietary Names (Prop. INN): List 26

p. 16 polidocanolum *delete whole entry*
 polidocanol

Supplement to WHO Chronicle, Vol. 29, No. 3, 1975

Proposed International Nonproprietary Names (Prop. INN): List 33

4 amilomerum *replace the definition by the following:*
 amilomer

Microspheres produced by reaction of partially hydrolysed starch with epichlorohydrin, quickly degradable by amylase (with a half-life of less than 120 minutes).
Name is followed by a hyphenated numerical code in which the number preceding the hyphen indicates the half-life in minutes and that following the hyphen indicates the mean diameter of the microspheres in μm : e.g. *amilomer 25-45* has a half-life of 25 minutes and a mean diameter of 45 μm . The methods of determining these parameters are approved by the competent national authority.

Supplement to WHO Chronicle, Vol. 35, No. 5, 1981

Proposed International Nonproprietary Names (Prop. INN): List 46

p. 3 *delete* *delete*
 cadexomerum iodium product of reaction of dextrin with epichlorohydrin coupled with ion-exchange
 cadexomer iodine groups and iodine

 insert *insert*
 cadexomerum carboxymethylated microspheres produced by reaction of partially hydrolysed
 cadexomer starch with epichlorohydrin; slowly degradable by amylase (with a half-life of
 more than 120 minutes).
Each cadexomer name is followed by a number referring to the mean diameter in μm of the microspheres: e.g. *cadexomer 110, 200*. The method of determining this parameter is approved by the competent national authority.

Supplement to WHO Chronicle, Vol. 36, No. 5, 1982

Proposed International Nonproprietary Names (Prop. INN): List 48

p. 6 *delete* *insert*
 cholini glycerophosphas cholini alfosceras
 choline glycerophosphate choline alfoscerate

Supplement to WHO Chronicle, Vol. 37, No. 5, 1983

Proposed International Nonproprietary Names (Prop. INN): List 50

p. 12 esmololum
esmolol

replace the chemical name and the CAS-registry number by the following:
(±)-methyl *p*-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate
103598-03-4

Supplement to WHO Chronicle, Vol. 38, No. 2, 1984

Proposed International Nonproprietary Names (Prop. INN): List 51

p. 6 eldexomerum
eldexomer

replace the definition by the following:

Microspheres produced by reaction of partially hydrolysed starch with epichlorhydrin, slowly degradable by amylase (with a half-life of more than 120 minutes).

Each eldexomer name is followed by a number referring to the mean diameter in µm of the microspheres e.g. *eldexomer 60*. The method of determining this parameter is approved by the competent national authority.

Supplement to WHO Chronicle, Vol. 40, No. 1, 1986

Proposed International Nonproprietary Names (Prop. INN): List 55

p. 9 *delete*
locicortonum
locicortone

insert
locicortoloni dicibas
locicortolone dicibate


WHO Drug Information, Vol. 1, No. 2, 1987

Proposed International Nonproprietary Names (Prop. INN): List 57

p. 103 niguldipinum
niguldipine

replace the chemical name, the graphic formula and the CAS-registry number by the following:

(+)-(S)-3-(4,4-diphenylpiperidino)propyl methyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate
113165-32-5



WHO Drug Information, Vol. 1, No. 3, 1987

Proposed International Nonproprietary Names (Prop. INN): List 58


p. 182 levdropropizinum
levdropropizine

replace the CAS registry number by the following.
99291-25-5

WHO Drug Information, Vol. 2, No. 2, 1988

Proposed International Nonproprietary Names (Prop. INN): List 59

- p. 4 cefcanelum *replace the graphic formula by the following:*
 cefcanel



- | | | |
|-------|---------------|---------------|
| p. 7 | <i>delete</i> | <i>insert</i> |
| | fronedipilum | fronepidilum |
| | fronedipil | fronepidil |
| p. 11 | <i>delete</i> | <i>insert</i> |
| | rosterelonum | rosterolonum |
| | rosterelone | rosterolone |

Procedure and Guiding Principles

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN-lists only.

CORRIGENDUM

WHO Drug Information, Vol. 2, No. 3, 1988

Recommended International Nonproprietary Names (Rec. INN): List 28

Owing to modifications in list 59 of proposed INNs (published in *WHO Drug Information*, Vol. 2, No. 2, 1988) the following corrections have to be made.

- | | | |
|--------|--------------|---------------------------|
| p. 164 | bendacololum | |
| | bendacolol | <i>delete whole entry</i> |
| p. 164 | clipoxaminum | |
| | clipoxamine | <i>delete whole entry</i> |